FINWIRES · TerminalLIVE
FINWIRES

C3.ai's Fiscal Q4 Results 'Good Step in Right Direction,' Wedbush Says

By

C3.ai's (AI) fiscal Q4 results are a "good step in the right direction," with restructuring savings expected in H2 of fiscal 2027, Wedbush said in a Thursday research note.

Wedbush said that with Tom Siebel back in the role of chief executive officer and the company's restructuring effort largely in the rearview mirror, it believes that C3.ai is now positioned to begin focusing on execution on its growth story.

With C3.ai expecting fiscal 2027 revenue in the range of $210 million to $240 million and adjusted operating loss between $128 million and $160 million, compared with Wall Street estimates of $224.7 million and $144.2 million loss, Wedbush said that the revenue midpoint implies a step down from fiscal 2026 but the reduced loss guide underscores cost discipline.

Wedbush reiterated the company's outperform rating with $15 price target.

Price: $10.64, Change: $-0.07, Percent Change: -0.65%

Related Articles

Wire

UnitedHealth, CVS, Cigna Seen Benefiting From Utilization Trends, AI Upside, Morgan Stanley Says

UnitedHealth (UNH), CVS Health (CVS) and Cigna (CI) are among the managed-care companies that could benefit from improving utilization trends and potential artificial intelligence-driven efficiency gains across the healthcare system, Morgan Stanley said in a note Thursday.The firm said early signs of softer utilization have supported recent gains in managed-care stocks. The group has delivered a series of medical-loss-ratio beats in Q1 and some companies raising guidance. However, it noted that investors are still awaiting clearer confirmation of underlying trends and utilization signals remaining mixed ahead of Q2 results.AI adoption is increasingly embedded across managed-care operations, including prior authorization, call centers, provider portals, care management, pharmacy utilization and payment integrity.Morgan Stanley said UnitedHealth stands out as a leading "AI enabler," particularly through Optum Insight initiatives, which support both efficiency gains and potential revenue upside.The firm's scenario analysis assumes 0.5% to 2.0% AI-driven insurance margin expansion, which could translate into an illustrative 18% to 71% EPS upside across managed-care companies. It added that administrative workflows, particularly prior authorization, remain key areas of automation potential.Morgan Stanley boosted its price targets on UnitedHealth, CVS Health, Elevance Health (ELV), Centene (CNC), Molina Healthcare (MOH), and Humana (HUM).Price: $399.90, Change: $+22.90, Percent Change: +6.07%

$CI$CNC$CVS$ELV$HUM$MOH$UNH
Wire

Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042

Nexalin Technology (NXL) said the US Patent and Trademark Office issued a patent expected to provide core intellectual property protection for its dynamic frequency stimulation method through 2042, strengthening its competitive position in deep-brain neurostimulation for depression and insomnia.The patent covers methods including transcranial alternating current stimulation, the company said Thursday in a statement.Price: $0.50, Change: $-0.03, Percent Change: -5.41%

$NXL
Wire

Rollins' Q2 Organic Growth, Margins to Accelerate Despite Higher Fuel Costs, RBC Says

Rollins' (ROL) organic growth in Q2 is likely to accelerate along with incremental margins despite near-term pressures from elevated fuel costs, RBC Capital Markets analysts said in a note emailed Thursday.Analysts said that Google search trends for "Pest Control" remain elevated compared with historical levels, with unique visits to pest control websites up 23% in April from a year earlier.RBC said that warmer and drier weather conditions in March and April have also likely increased pest activity, further supporting industry tailwinds.For Rollins, analysts expect margin expansion into the high-20% range in Q2, driven by accelerating organic growth, normalization of insurance and claims expenses, and operating leverage from higher volumes.RBC maintained its outperform rating and a $67 price target on the stock.Price: $46.37, Change: $+0.58, Percent Change: +1.27%

$ROL